As far as I understand, no patients with Psoriasis
Post# of 72436
![](/assets/46931549/no_avatar_available_thumb.jpg)
"This study is designed as an open-label, randomized, 2-period, 2-treatment, 2-sequence, single-dose intensive pharmacokinetic (PK) study conducted in healthy volunteers.
https://clinicaltrials.gov/ct2/show/NCT02101216
Also, I believe the 2a was a crossover study rather than dose optimization study but if anyone knows I am missing something please do tell.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)